MDNA209 / Medicenna, Stanford University - LARVOL DELTA

Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference (GlobeNewswire) - "Medicenna Therapeutics...announced today that the Company will present two abstracts, both as oral presentations, at the Promise of Interleukin-2 Therapy Conference, taking place at the Centre International de Conférences Sorbonne Université in Paris, France, from September 4-7, 2024. The Company will present preclinical data for the first time on its MDNA209 platform, featuring long-acting, high-affinity IL-2β biased IL-2/IL-15 Super-antagonists with therapeutic potential for autoimmune and graft-versus-host diseases. Additionally, further preclinical data will be presented on MDNA113, the Company’s novel first-in-class IL-13Rα2 tumor-targeted and tumor-activated bifunctional anti-PD1-IL-2 Superkine."

Preclinical • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • Oncology